Cargando…

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia

The treatment of chronic lymphocytic leukemia (CLL) has evolved over the past decade. Our better understanding of disease biology and risk stratification has allowed delivering more effective therapies. In fact, front-line chemoimmunotherapy has demonstrated improvement in overall survival when comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabhan, Chadi, Kay, Neil E.
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076040/
https://www.ncbi.nlm.nih.gov/pubmed/21499555
http://dx.doi.org/10.4137/CMO.S4087
_version_ 1782201807242526720
author Nabhan, Chadi
Kay, Neil E.
author_facet Nabhan, Chadi
Kay, Neil E.
author_sort Nabhan, Chadi
collection PubMed
description The treatment of chronic lymphocytic leukemia (CLL) has evolved over the past decade. Our better understanding of disease biology and risk stratification has allowed delivering more effective therapies. In fact, front-line chemoimmunotherapy has demonstrated improvement in overall survival when compared to chemotherapy in randomized studies. Yet, treatment of relapsed CLL remains challenging and few agents are effective in that setting. Ofatumumab (Ofa) is a humanized monoclonal antibody targeted against CD20 with demonstrable activity in rituximab-resistant CLL cell lines. This agent was recently approved for the treatment of relapsed/refractory CLL patients who have failed fludarabine and alemtuzumab. In this review, we provide a historical perspective on approaches to CLL as front-line and in the relapsed setting. We further summarize novel anti-CD20 antibodies with specific emphasis on ofa. We review studies that led to ofatumumab’s approval including pre-clinical data, trials using ofa in combination therapies, and adverse events/toxicities reported with this agent.
format Text
id pubmed-3076040
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-30760402011-04-15 The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia Nabhan, Chadi Kay, Neil E. Clin Med Insights Oncol Review The treatment of chronic lymphocytic leukemia (CLL) has evolved over the past decade. Our better understanding of disease biology and risk stratification has allowed delivering more effective therapies. In fact, front-line chemoimmunotherapy has demonstrated improvement in overall survival when compared to chemotherapy in randomized studies. Yet, treatment of relapsed CLL remains challenging and few agents are effective in that setting. Ofatumumab (Ofa) is a humanized monoclonal antibody targeted against CD20 with demonstrable activity in rituximab-resistant CLL cell lines. This agent was recently approved for the treatment of relapsed/refractory CLL patients who have failed fludarabine and alemtuzumab. In this review, we provide a historical perspective on approaches to CLL as front-line and in the relapsed setting. We further summarize novel anti-CD20 antibodies with specific emphasis on ofa. We review studies that led to ofatumumab’s approval including pre-clinical data, trials using ofa in combination therapies, and adverse events/toxicities reported with this agent. Libertas Academica 2011-03-24 /pmc/articles/PMC3076040/ /pubmed/21499555 http://dx.doi.org/10.4137/CMO.S4087 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Nabhan, Chadi
Kay, Neil E.
The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
title The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
title_full The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
title_fullStr The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
title_full_unstemmed The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
title_short The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
title_sort emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076040/
https://www.ncbi.nlm.nih.gov/pubmed/21499555
http://dx.doi.org/10.4137/CMO.S4087
work_keys_str_mv AT nabhanchadi theemergingroleofofatumumabinthetreatmentofchroniclymphocyticleukemia
AT kayneile theemergingroleofofatumumabinthetreatmentofchroniclymphocyticleukemia
AT nabhanchadi emergingroleofofatumumabinthetreatmentofchroniclymphocyticleukemia
AT kayneile emergingroleofofatumumabinthetreatmentofchroniclymphocyticleukemia